Renal clearable polyfluorophore nanosensors for early diagnosis of cancer and allograft rejection
Source abstract
Abstract
Optical nanoparticles are promising diagnostic tools; however, their shallow optical imaging depth and slow clearance from the body have impeded their use for in vivo disease detection. To address these limitations, we develop activatable polyfluorophore nanosensors with biomarker-triggered nanoparticle-to-molecule pharmacokinetic conversion and near-infrared fluorogenic turn-on response. Activatable polyfluorophore nanosensors can accumulate at the disease site and react with disease-associated proteases to undergo in situ enzyme-catalysed depolymerization. This disease-specific interaction liberates renal-clearable fluorogenic fragments from activatable polyfluorophore nanosensors for non-invasive longitudinal urinalysis and outperforms the gold standard blood and urine assays, providing a level of sensitivity and specificity comparable to those of invasive biopsy and flow cytometry analysis. In rodent models, activatable polyfluorophore nanosensors enable ultrasensitive detection of tumours (1.6 mm diameter) and early diagnosis of acute liver allograft rejection. We anticipate that our modular nanosensor platform may be applied for early diagnosis of a range of diseases via a simple urine test.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Quantum Dots Synthesis And Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Park, S. M., Aalipour, A., Vermesh, O., Yu, J. H. & Gambhir, S. S. Towards clinically translatable in vivo nanodiagnostics. Nat. Rev. Mater. 2, 17014 (2017).10.1038/natrevmats.2017.14 ↗
2. Lovell, J. F. et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat. Mater. 10, 324–332 (2011).10.1038/nmat2986 ↗
3. Miao, Q. et al. Molecular afterglow imaging with bright, biodegradable polymer nanoparticles. Nat. Biotechnol. 35, 1102–1110 (2017).10.1038/nbt.3987 ↗
4. Zhou, W., Han, Y., Beliveau, B. J. & Gao, X. Combining Qdot nanotechnology and DNA nanotechnology for sensitive single‐cell imaging. Adv. Mater. 32, 1908410 (2020).10.1002/adma.201908410 ↗
5. Li, J. et al. Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. Nat. Biomed. Eng. 1, 0082 (2017).10.1038/s41551-017-0082 ↗
6. Liang, K. et al. Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. Nat. Biomed. Eng. 1, 0021 (2017).10.1038/s41551-016-0021 ↗
7. The risks of nanomaterial risk assessment. Nat. Nanotechnol. 15, 163–163 (2020).10.1038/s41565-020-0658-9 ↗
8. Lu, Y., Aimetti, A. A., Langer, R. & Gu, Z. Bioresponsive materials. Nat. Rev. Mater. 2, 16075 (2016).10.1038/natrevmats.2016.75 ↗
9. Du, B., Yu, M. & Zheng, J. Transport and interactions of nanoparticles in the kidneys. Nat. Rev. Mater. 3, 358–374 (2018).10.1038/s41578-018-0038-3 ↗
10. Tsoi, K. M. et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 15, 1212–1221 (2016).10.1038/nmat4718 ↗
11. Poon, W. et al. Elimination pathways of nanoparticles. ACS Nano 13, 5785–5798 (2019).10.1021/acsnano.9b01383 ↗
12. Yu, M. X. & Zheng, J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano 9, 6655–6674 (2015).10.1021/acsnano.5b01320 ↗
13. Du, B. et al. Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime. Nat. Nanotechnol. 12, 1096–1102 (2017).10.1038/nnano.2017.170 ↗
14. Choi, H. S. et al. Renal clearance of nanoparticles. Nat. Biotechnol. 10, 1165–1170 (2007).10.1038/nbt1340 ↗
15. Hong, G., Antaris, A. L. & Dai, H. Near-infrared fluorophores for biomedical imaging. Nat. Biomed. Eng. 1, 0010 (2017).10.1038/s41551-016-0010 ↗
16. Perrault, S. D. & Chan, W. C. In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl Acad. Sci. USA 107, 11194–11199 (2010).10.1073/pnas.1001367107 ↗
17. Zhao, T. et al. A transistor-like pH nanoprobe for tumour detection and image-guided surgery. Nat. Biomed. Eng. 1, 0006 (2016).10.1038/s41551-016-0006 ↗
18. Yuan, Y. et al. Intracellular self-assembly of cyclic d-luciferin nanoparticles for persistent bioluminescence imaging of fatty acid amide hydrolase. ACS Nano 10, 7147–7153 (2016).10.1021/acsnano.6b03412 ↗
19. Gao, Y., Shi, J., Yuan, D. & Xu, B. Imaging enzyme-triggered self-assembly of small molecules inside live cells. Nat. Commun. 3, 1033 (2012).10.1038/ncomms2040 ↗
20. Ye, D. et al. Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat. Chem. 6, 519 (2014).10.1038/nchem.1920 ↗
21. Yuan, Y. et al. Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. Nat. Mater. 18, 1376–1383 (2019).10.1038/s41563-019-0503-4 ↗
22. Xie, C., Zhen, X., Lyu, Y. & Pu, K. Nanoparticle regrowth enhances photoacoustic signals of semiconducting macromolecular probe for in vivo imaging. Adv. Mater. 29, 1703693 (2017).10.1002/adma.201703693 ↗
23. Huynh, E. et al. In situ conversion of porphyrin microbubbles to nanoparticles for multimodality imaging. Nat. Nanotechnol. 10, 325–332 (2015).10.1038/nnano.2015.25 ↗
24. Kwon, E. J., Dudani, J. S. & Bhatia, S. N. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat. Biomed. Eng. 1, 0054 (2017).10.1038/s41551-017-0054 ↗
25. Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14, 883–890 (2019).10.1038/s41565-019-0527-6 ↗
26. Jiang, X., Du, B. & Zheng, J. Glutathione-mediated biotransformation in the liver modulates nanoparticle transport. Nat. Nanotechnol. 14, 874–882 (2019).10.1038/s41565-019-0499-6 ↗
27. Verdoes, M. et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J. Am. Chem. Soc. 135, 14726–14730 (2013).10.1021/ja4056068 ↗
28. He, S., Li, J., Lyu, Y., Huang, J. & Pu, K. Near-infrared fluorescent macromolecular reporters for real-time imaging and urinalysis of cancer immunotherapy. J. Am. Chem. Soc. 142, 7075–7082 (2020).10.1021/jacs.0c00659 ↗
29. Pashayan, N. & Pharoah, P. D. The challenge of early detection in cancer. Science 368, 589–590 (2020).10.1126/science.aaz2078 ↗
30. Wood, K. J., Bushell, A. & Hester, J. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12, 417–430 (2012).10.1038/nri3227 ↗
31. Tiegs, G., Hentschel, J. & Wendel, A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90, 196–203 (1992).10.1172/JCI115836 ↗
32. Yamashita, J. et al. Apolipoprotein A-II suppressed concanavalin A-induced hepatitis via the inhibition of CD4 T cell function. J. Immunol. 186, 3410–3420 (2011).10.4049/jimmunol.1002924 ↗
33. Lechler, R. I., Sykes, M., Thomson, A. W. & Turka, L. A. Organ transplantation—how much of the promise has been realized? Nat. Med. 11, 605–613 (2005).10.1038/nm1251 ↗
34. Jones, K. D. & Ferrell, L. D. Interpretation of biopsy findings in the transplant liver. Semin. Diagn. Pathol. 15, 306–317 (1998).
35. Portmann, B., Slapak, G., Gane, E. & Williams, R. Pathology and biopsy diagnosis of the transplanted liver. Verh. Dtsch Ges. Pathol. 79, 277–290 (1995).
36. Welt, S. et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12, 1193–1203 (1994).10.1200/JCO.1994.12.6.1193 ↗
37. Erdi, Y. E. Limits of tumor detectability in nuclear medicine and PET. Mol. Imaging Radionucl. Ther. 21, 23–28 (2012).10.4274/Mirt.138 ↗
38. Serres, S. et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl Acad. Sci. USA 109, 6674–6679 (2012).10.1073/pnas.1117412109 ↗
39. Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013).10.1038/nbt.2464 ↗
40. Soleimany, A. P. & Bhatia, S. N. Activity-based diagnostics: an emerging paradigm for disease detection and monitoring. Trends Mol. Med. 26, 450–468 (2020).10.1016/j.molmed.2020.01.013 ↗
41. Aalipour, A. et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat. Biotechnol. 37, 531–539 (2019).10.1038/s41587-019-0064-8 ↗
42. Kirkpatrick, J. D. et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci. Transl. Med. 12, eaaw0262 (2020).10.1126/scitranslmed.aaw0262 ↗
43. Dravid, V. et al. Arterial abnormalities following orthotopic liver transplantation: arteriographic findings and correlation with Doppler sonographic findings. Am. J. Roentgenol. 163, 585–589 (1994).10.2214/ajr.163.3.8079850 ↗
44. Ogura, Y. et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology 214, 795–800 (2000).10.1148/radiology.214.3.r00mr34795 ↗
45. Shah, A. N., Dodson, F. & Fung, J. Role of nuclear medicine in liver transplantation. Semin. Nucl. Med. 25, 36–48 (1995).10.1016/S0001-2998(05)80005-4 ↗
46. Huang, J., Li, J., Lyu, Y., Miao, Q. & Pu, K. Molecular optical imaging probes for early diagnosis of drug-induced acute kidney injury. Nat. Mater. 18, 1133–1143 (2019).10.1038/s41563-019-0378-4 ↗
47. Benson, R. C. & Kues, H. A. Absorption and fluorescence properties of cyanine dyes. J. Chem. Eng. Data 22, 379–383 (1977).10.1021/je60075a020 ↗
48. Gu, K. et al. Real-time tracking and in vivo visualization of β-galactosidase activity in colorectal tumor with a ratiometric near-infrared fluorescent probe. J. Am. Chem. Soc. 138, 5334–5340 (2016).10.1021/jacs.6b01705 ↗
49. Hu, J. J. et al. Fluorescent probe HKSOX-1 for imaging and detection of endogenous superoxide in live cells and in vivo. J. Am. Chem. Soc. 137, 6837–6843 (2015).10.1021/jacs.5b01881 ↗
50. Hee Ryu, J. et al. Cathepsin B-sensitive nanoprobe for in vivo tumor diagnosis. J. Mater. Chem. 21, 17631–17634 (2011).10.1039/c1jm13064a ↗
51. Ding, Y. et al. Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. Theranostics 10, 5195–5208 (2020).10.7150/thno.45017 ↗
52. Kamada, N. & Calne, R. Y. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 28, 47–50 (1979).10.1097/00007890-197907000-00011 ↗
53. Guo, L. et al. Significant enhancement by anti‐ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver transplantation. Liver Transplant. 10, 743–747 (2004).10.1002/lt.20167 ↗
54. Medicherla, S. et al. Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig. J. Inflamm. Res. 3, 9–16 (2010).10.2147/JIR.S6718 ↗
55. Wang, W. et al. Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice. Am. J. Physiol. Ren. Physiol. 293, F1131–F1136 (2007).10.1152/ajprenal.00212.2007 ↗